Join our daily newsletter At The Bell to receive exclusive market insights
Race Oncology (ASX:RAC) has sought to expand the total addressable markets it can reach with its cancer drug RC220, on Monday launching a Phase Three Acute Myeloid Leukemia (AML) trial, “bridging RC110 to RC220 providing a… low-cost pathway to regulatory approval of RC220.”
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Meanwhile, having recently fleshed out the mechanism of action of bisantrene, the company’s chemo-without-side-effects drug, Race will also be launching a non-small cell lung cancer (NSCLC) trial.
In the background, the company continues to focus on the ‘cardioprotective and anticancer properties of bisantrene’ – suggesting these new focuses could perhaps offer the company more clinical direction in 2026.
To take it from the company in 12-gauge scientific language: “The discovery that (E,E)-bisantrene, the active drug in RC220, is a DNA/RNA G-quadruplex (G4) binder has identified a major clinical and commercial opportunity for RC220 in mutated epidermal growth factor receptor (EGFRm) driven NSCLC,” Race wrote on Monday.
“In addition to the EGFRm NSCLC trial program, Race Oncology has identified a rapid and cost-effective clinical pathway to potential regulatory approval of RC220 in relapsed/refractory AML.
“This Phase 3 program includes a bridging and dose optimisation stage to establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of RC220 with the original RC110 formulation.”
Long story short, the company is now testing RC220 on a bad form of leukemia and a type of lung cancer. The market liked that news; Race’s shares were up +6% heading into lunchtime trades.
RAC last traded at $3.54/sh.
Join the discussion: See what HotCopper users are saying about Race Oncology Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
